首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Onchocerciasis in Ecuador: evolution of chorioretinopathy after amocarzine treatment.
【2h】

Onchocerciasis in Ecuador: evolution of chorioretinopathy after amocarzine treatment.

机译:厄瓜多尔盘尾丝虫病:阿莫卡因治疗后脉络膜视网膜病变的演变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

AIMS: To investigate the impact of the macrofilaricidal drug, amocarzine, on the evolution of chorioretinopathy in onchocerciasis. METHODS: A prospective uncontrolled cohort study was performed using subjects infected with Onchocerca volvulus in a hyperendemic onchocerciasis focus in Esmeraldas Province in Ecuador. Study subjects were recruited into four cohorts in which ophthalmic and parasitological data were collected for 2, 3, 4, and 5 years respectively. RESULTS: Complete ophthalmic follow up was obtained for 294 individuals in the four cohorts. The incidence of retinal pigment epithelial atrophy tended to remain constant between cohorts while that of chorioretinal scarring with a greater observation period. The incidence rate of cases with new or extending chorioretinal lesions was greater with an increasing period of follow up. An association was seen between the cumulative microfilarial loads in the skin and the development of new chorioretinal lesions (p < 0.05). No relation was noted between cumulative microfilarial loads and the progression of existing disease. CONCLUSION: Amocarzine therapy did not prevent the natural evolution of chorioretinal disease. It was suggested that ocular microfilariae were necessary for the induction of chorioretinopathy in previously unaffected eyes and that extension of existing disease might also be related to the presence of ocular microfilariae or to other immunological mechanisms.
机译:目的:研究大丝杀伤药物阿莫卡因对盘尾丝虫病脉络膜视网膜病变的演变的影响。方法:在厄瓜多尔埃斯梅拉达斯省的高流行性盘尾丝虫病病灶中,使用感染了盘尾丝虫的受试者进行了一项前瞻性非对照队列研究。研究对象被分为四个队列,分别收集了2、3、4和5年的眼科和寄生虫学数据。结果:四个队列中的294人获得了完整的眼科随访。队列之间视网膜色素上皮萎缩的发生率倾向于保持恒定,而脉络膜视网膜瘢痕的发生率具有较大的观察期。随着随访时间的延长,新的或扩展的脉络膜视网膜病变病例的发生率更高。皮肤中累积的微丝负荷与新的脉络膜视网膜病变的发展之间存在关联(p <0.05)。累积的微丝负荷与现有疾病的进展之间没有关系。结论:阿莫卡因治疗不能预防脉络膜视网膜疾病的自然发展。有人认为,在以前未患病的眼睛中诱发眼脉络膜视网膜病变需要眼部微丝aria病,而现有疾病的扩展也可能与眼部微丝presence病的存在或其他免疫机制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号